# Caffeine vs. ALA in BMS Treatment. (BMS: Burning Mouth Syndrome. ALA: Alpha-Lipoic Acid.)

> **NCT06195137** · NA · COMPLETED · sponsor: **Lu Jiang** · enrollment: 130 (actual)

## Conditions studied

- Caffeine
- Burning Mouth Syndrome

## Interventions

- **DIETARY_SUPPLEMENT:** Caffeine
- **DRUG:** Alpha Lipoic Acid

## Key facts

- **NCT ID:** NCT06195137
- **Lead sponsor:** Lu Jiang
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-13
- **Primary completion:** 2023-06-15
- **Final completion:** 2023-06-23
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2024-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06195137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06195137, "Caffeine vs. ALA in BMS Treatment. (BMS: Burning Mouth Syndrome. ALA: Alpha-Lipoic Acid.)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06195137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*